From reducing adult dosages for children to the lack of pediatric-specific formulations; from insufficient pediatric clinical data to limited access to medicines for children with rare diseases, pediatric medication challenges are not limited to one country alone, but represent a ...Learn More

On July 23, 2026, China's National Medical Products Administration (NMPA) approved a new indication for Famitinib, a Class 1 innovative drug independently developed by Hengrui Pharmaceuticals, in combination with the PD-1 inhibitor Camrelizumab for the first-line treatment of ...Learn More

A spinal cord tumor is a tumor that develops within the spinal cord or the tissues surrounding it. These tumors may be benign or malignant and are generally classified according to their location as intramedullary tumors, intradural extramedullary tumors, or extradural ...Learn More

As global population aging continues to accelerate, the management of chronic diseases has become a major challenge for healthcare systems worldwide. Conditions such as hypertension, diabetes, coronary artery disease, chronic kidney disease, and neurological disorders often ...Learn More

In recent years, GLP-1 receptor agonists (GLP-1 RAs) have been sweeping across the global pharmaceutical market at an unprecedented pace. Originally developed for the treatment of type 2 diabetes, they have now become an important direction for weight management, metabolic ...Learn More